~~<i id='1E879CFD4D'><strike id='1E879CFD4D'><tt id='1E879CFD4D'><pre id='1E879CFD4D'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：explore 2025-08-12 01:06:28 Page View：64145

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dario to buy mental health app maker Twill in cash and stock deal
Next article： Alkermes shareholders re

comprehensive

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Why depression after traumatic brain injury is distinct

AdobeTraumaticbraininjurymultipliestheriskofmajordepressioneightfold.Whiletheemotionaltraumaofwhatev

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

6 phony surgeries that take placebo to the extreme

AFP/GettyImagesMostofthetime,it’seasytobeintheplacebogroup ofaclinicaltrial:nosideeffects,minimalann